olfactory receptor family 51 subfamily F member 4 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR51F4P profile across patient tissues and cancer cell-line models. OR51F4P expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, OR51F4P is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, OR51F4P RNA expression shows 6,391 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, PRAD, and STAD as cancer lineages where OR51F4P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR51F4P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR51F4P survival associations across molecular data types. OR51F4P RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR51F4P RNA expression–survival associations across cancer types. High OR51F4P expression shows unfavorable associations in KICH, ESCA, KIRC, SKCM, THCA and PCPG. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for OR51F4P RNA expression.
This table summarizes OR51F4P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR51F4P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR51F4P shows higher tumor expression in PRAD. The PRAD box plot shows higher OR51F4P RNA expression in tumor versus normal tissue (log2 FC = +0.254, t-test p < 0.001).
This table shows molecular features associated with OR51F4P in patient tissues and cancer cell lines. In patient samples, OR51F4P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
